@[email protected] http://OncologyTube.com had the pleasure of speaking with Dr. Kaklamani about Elacestrant.
https://oncologytube.com/v/41478
🐦🔗: https://twitter.com/oncologytube/status/1620116074338607104
Philippe Aftimos
- 33 Followers
- 54 Following
- 81 Posts
Medical oncologist at Institut Jules Bordet in Brussels. Breast cancer, clinical research, Union Saint-Gilloise 💛💙, music, photography, poetry, in no particular order. Born in Lebanon 🇱🇧, Belgian (Brussels) 🇧🇪 by choice.
In Annals of Oncology, a report on the STING (NCT04932525) study in which patients with advanced cancer had molecular profiling using a ctDNA sequencing assay 🩸🧬 and were assigned matched therapy 💊 as per a molecular tumor board. https://www.annalsofoncology.org/article/S0923-7534(23)00046-7/fulltext
@[email protected] @[email protected]
🐦🔗: https://twitter.com/Annals_Oncology/status/1619997528812048385
The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?
🐦🔗: https://twitter.com/VKaklamani/status/1619858718467985408
VIRGINIA KAKLAMANI on Twitter
“The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?”
The #OncoAlertColloquium 🚨Pls SHARE‼️
Day1⃣ #BreastCancer
https://youtu.be/T1mXJjGJRN4
Day2⃣GU Onc
https://youtu.be/Ph8BfNDM9Qk
Day3⃣ #LungCancer
https://youtu.be/XxcFJd5CJ8M
Day4⃣ #GynOnc
https://youtu.be/25BwcEBKo-E
Day5⃣GI Onc
https://youtu.be/r0a913rSge0
Day6⃣Nursing
https://youtu.be/Our4DpN1Dqc
🐦🔗: https://twitter.com/OncoAlert/status/1619406322600120320
The 2022 OncoAlert Colloquium DAY 1: Breast Cancer
Ongoing and planned Elacestrant clinical trials:
- In brain mets with abemaciclib https://clinicaltrials.gov/ct2/show/NCT04791384?cond=elacestrant&draw=2&rank=7
https://clinicaltrials.gov/ct2/show/NCT05386108?cond=elacestrant&draw=2&rank=6
- In combination with targeted therapies https://clinicaltrials.gov/ct2/show/NCT05563220?cond=elacestrant&draw=2&rank=8
- To treat ctDNA relapse in early HR+/HER2- BC https://clinicaltrials.gov/ct2/show/NCT05512364?cond=elacestrant&draw=2&rank=2
#bcsm (COI)
Elacestrant results publications:
- Phase 1 dose escalation clinical trial: https://pubmed.ncbi.nlm.nih.gov/33513026/
- Phase 1b with FES-PET/CT as a pharmacodynamic biomarker: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01333-3
- The EMERALD pivotal phase 3 clinical trial: https://ascopubs.org/doi/10.1200/JCO.22.00338?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer - PubMed
Elacestrant 400 mg orally once daily has an acceptable safety profile and demonstrated single-agent activity with confirmed partial responses in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer. Notably, responses were observed in patients with <i>ESR1</i> mutatio …
FDA approves elacestrant, oral SERD, for ESR1-mutated ER+ metastatic breast cancer, based on phase 3 EMERALD clinical trial. Last endocrine therapy approved was ~ 20 years ago. #bcsm @[email protected] Link to article and label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf https://ascopubs.org/doi/pdf/10.1200/JCO.22.00338?role=tab
🐦🔗: https://twitter.com/dradityabardia/status/1619074675186999297
Elacestrant approved for esr1m mbc. A journey that started from the phase 1 trial here at @[email protected] with the collaboration of Aditya Bardia to the phase 3 EMERALD trial showing significant improvement compared with soc et. @[email protected] @[email protected]
🐦🔗: https://twitter.com/VKaklamani/status/1619074478692257792
A first oral SERD @[email protected] approval! More convenient administration schema & efficacy data in the ESR1m setting.
A huge thanks to the patients that participated in the clinical trials and their families. I feel humbled and privileged for taking part in the development #bcsm
A huge thanks to the patients that participated in the clinical trials and their families. I feel humbled and privileged for taking part in the development #bcsm